Our findings are in accordance to Anders et al. 17 study, which showed a higher prevalence of Her2 + (52% vs 24%) and triple negative tumours (7% vs 2.6%) among young women compared to older women, but differed from it about the incidence of ER/PgR + tumours, which resulted lower in younger patients compared to older ones in Anders et al.’s study (71% vs 80%). This evidence concerns the gene ERBB2 and neoplasm.